Ron H van Schaik, Professor, Erasmus University, Rotterdam, the Netherlands (3) YouTube
Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. ML Becker, LE Visser, RHN van Schaik, A Hofman, AG Uitterlinden,. Diabetes 58 (3), 745-749. , 2009. 313.
Faculty of Pharmaceutical Sciences Ron van Schaik, PhD Michael Smith Laboratories
Prof. Dr. Ron van Schaik studied Chemistry at Utrecht University, with specialisations in Biochemistry, Molecular Biology and Clinical Chemistry. He did his PhD on Molecular cloning and Immunological localization of PLA2 at the Dept. Biochemistry of the Center of Biomembranes and Lipid Research (CBML) at Utrecht University,. A 4 year post-doc at the Dept. Endocrinology, Erasmus MC Rotterdam on.
Interview Prof. Ron H. van Schaik YouTube
prof. dr. Ron van Schaik Full professor, Erasmus MC, Clinical Chemistry https://orcid.org/0000-0003-1864-2151 Overview Fingerprint Network Research output (402) Similar Profiles (1) Supervised Work (5) If you made any changes in Pure these will be visible here soon. Fingerprint Dive into the research topics where Ron van Schaik is active.
Ronald van Schaik Werf&
New insights were provided by the esteemed keynote speakers, André G. Uitterlinden, Ron H.N. van Schaik, Roos van Westrhenen and all other speakers, Lone Fisker, Jordan Moore, Tiffany Morris, PhD.
Prof. Dr. Ron H.N. van Schaik Laboratoriumspecialist Erasmus MC
Pharmacogenetics International Expertcenter - Prof. Dr. Ron H.N. van Schaik - Erasmus MC Research group/lab | Prof. Dr. Ron H.N. van Schaik Pharmacogenetics International Expertcenter Research is aimed at discovery and implementation of DNA analysis for personalizing drug therapy About our research group/lab Our research Key Publications
Ron van Schaik Owner CGA Web Design LinkedIn
Awesome Books: your haven for affordable literary gems. Quality reads, unbeatable prices. Our extensive selection caters to all readers. Discover your next favourite book with us.
Forward Thinking An Interview with Ron Van Schaik PMF Features
Interview Ron van Schaik 20 mei 2021 'Iedereen heeft recht op een DNA-paspoort' Ron van Schaik Professor farmacogenetica Nederland is vooralsnog het enige land ter wereld waar patiënten bij de apotheek medicatie op maat kunnen krijgen op basis van hun DNA-profiel.
Interview Ron van Schaik
Ron H.N. van Schaik Full Professor Pharmacogenetics / Head Dept Clinical Chemistry / Past-President European Society Pharmacogenomics & Personalised Therapy (ESPT) 10mo
Ron H van Schaik, Professor, Erasmus University, Rotterdam, the Netherlands (5) YouTube
31 okt. 2015 Activiteit Je gezondheid begint in je buik. Dat is me wel weer duidelijk geworden. Ik had vandaag een inspirerende eerste dag als directeur-bestuurder van de… Gemarkeerd als.
Media Tweets by Ron van Schaik (CGA_Web) Twitter
Andrews, Louise ; Hesselink, Dennis; van Schaik, Ron et al. / A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients.In: British Journal of Clinical Pharmacology. 2019 ; Vol. 85, No. 3. pp. 601-615.
Interview Ronald van Schaik (Kaliber) op The Social Conference 2017 YouTube
Prof. Dr. Ron van Schaik, PhD is a registered European specialist Laboratory medicine (2003) and a Full Professor of Pharmacogenetics (2013). He is working at the Dept. Clinical Chemistry at the Erasmus University Medical Center Rotterdam, The Netherlands.
Ron van Schaik Associate Professor Erasmus MC XING
Ron van Schaik Cytochrome P450 3A4 (CYP3A4) is the most important drug metabolizing enzyme in the liver, responsible for the oxidative metabolism of ∼50% of clinically prescribed drugs.
Nieuwe inzichten helpen patiënt in strijd tegen depressie Siemens Healthineers Nederland
Contact External Profile About Introduction Publications Other positions Profile of R.H.N. van Schaik, PhD, Erasmus MC, Rotterdam, Professor Pharmacogenetics.
Ron van Schaik Leadership and Change consultant Boertien Vergouwen Overduin LinkedIn
Simple Summary Although the introduction of programmed cell death 1 (PD-1) immune checkpoint inhibitors (ICIs) has significantly improved the overall survival (OS) in patients with metastatic.
Ron van Schaik • BioTech Pharma Summit
Ron H.N. van Schaik's Post Ron H.N. van Schaik Full Professor Pharmacogenetics / Head Dept Clinical Chemistry / Past-President European Society Pharmacogenomics & Personalised Therapy (ESPT)
Ron SCHAIK Professor Erasmus MC, Rotterdam Erasmus MC Department of Clinical Chemistry (AKC)
Ron SCHAIK | Cited by 18,852 | of Erasmus MC, Rotterdam (Erasmus MC) | Read 541 publications | Contact Ron SCHAIK
